Donald G. Morris

Calgary, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation.

Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: March 20, 2025

The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada.

The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 19, 2022

Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.

Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.

Journal: The journal of pathology. Clinical research

Published: January 07, 2020

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.

Journal: Cancers

Published: October 16, 2019

Machine learning for prediction of cutaneous adverse events in patients receiving anti-PD-1 immunotherapy.

Machine learning for prediction of cutaneous adverse events in patients receiving anti-PD-1 immunotherapy.

Journal: Journal of the American Academy of Dermatology

Published: September 11, 2019

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.

Journal: Cancers

Published: May 17, 2018

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 20, 2017

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.

Journal: Blood cancer journal

Published: July 27, 2017

Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.

Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.

Journal: PloS one

Published: January 13, 2017

Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.

Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 18, 2016

Biobanking in the Twenty-First Century: Driving Population Metrics into Biobanking Quality.

Biobanking in the Twenty-First Century: Driving Population Metrics into Biobanking Quality.

Journal: Advances in experimental medicine and biology

Published: October 01, 2015

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

Journal: Investigational new drugs

Published: May 28, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026